@article{oai:niigata-u.repo.nii.ac.jp:00020026,
 author = {岩渕, 眞 and 大沢, 義弘 and 内山, 昌則 and 松田, 由紀夫 and 内藤, 真一 and 広田, 雅行 and 内藤, 万砂文 and 近藤, 公男 and 内海, 治郎 and 浅見, 恵子 and 笹崎, 義博 and 小田, 良彦 and 佐藤, 雅久},
 issue = {7},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Jul},
 note = {Twenty-two pediatric patients with a stage IV-A or IV-B neuroblastoma have been treated with multimodal therapy consisting of intensive chemotherapy and surgery at Niigata University Hospital since 1985. The patients first received six cyclic courses of intensive chemotherapy ［regimen A_1］, consisting of cyclophosphamide ［1,200mg/m^2］, vincristine ［1.5mg/m^2], tetrahydropyranyl adriamycin ［pyrarubicin 40mg/m^2］, and cisplatin ［90mg/m^2］. Primary tumors and involved regional lymph nodes were removed sometime during first six cycles of chemotherapy. After the six cycles of ［Regiment A_1］, patients received alternating treatment with ［Regimen A_2］consisting of cyclophophamide ［1,500mg/m^2］, THP-adriamycin ［50mg/m^2］, cisplatin ［90mg/m^2］, and ［Regimen C］consisting of cyclophosphamide ［1,500mg/m^2］, DTIC ［250mg/m^2］. Two-year survival rate was 59%. Nine patients have now survived with disease free at 2 years after initiation of the treatment （survival rate: 41%）. From the viewpoint of prognosis, the influencing factors are as follows: small round cell type, diploidy, VMA（－）, NSE more than 100ng/ml, N-myc over 8 times of normal value.},
 pages = {551--558},
 title = {進行神経芽腫に対する統一プロトコールによる集学的治療の検討},
 volume = {107},
 year = {1993}
}